Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 2, 2009, Pages 14-21

  Gisondi, P ^a   Girolomoni, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

cardiovascular risk; metabolic syndrome; obesity; psoriasis

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; COMORBIDITY; DYSLIPIDEMIA; GENETIC ASSOCIATION; HEART INFARCTION; HEART MUSCLE METABOLISM; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PSORIASIS; STROKE;

CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; METABOLIC DISEASES; PSORIASIS;

EID: 76749155040     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73373-3     Document Type: Article

References (70)

1. Gudjonsson J.E., and Elder J.T. Psoriasis: epidemiology. Clin Dermatol 25 (2007) 535-546
2. Zippin J.H. The genetics of psoriasis. J Drugs Dermatol 8 (2009) 414-417
3. Nestle F.O. Psoriasis. Curr Dir Autoimmun 10 (2008) 65-75
4. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
5. Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. J Autoimmun 25 (2005) 69-73
6. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128 (2008) 1207-1211
7. Albanesi C., Scarponi C., Cavani A., Federici M., Nasorri F., and Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 115 (2000) 81-87
8. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118 (2008) 597-607
9. Albanesi C., Scarponi C., Pallotta S., Daniele R., Bosisio D., Madonna S., et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 206 (2009) 249-258
10. Prodanovich S., Shelling M.L., Federman D.G., and Kirsner R.S. Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases. Arch Dermatol 144 (2008) 1518-1519
11. Tordjman J., Guerre-Millo M., and Clément K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab 34 (2008) 658-663
12. Alamanos Y., Voulgari P.V., and Drosos A.A. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35 (2008) 1354-1358
13. Gisondi P., Girolomoni G., Sampogna F., Tabolli S., and Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 15 (2005) 279-283
14. Gisondi P., Tinazzi I., El-Dalati G., Gallo M., Biasi D., Barbara L.M., et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 67 (2008) 26-30
15. Husted J.A., Tom B.D., Farewell V.T., Schentag C.T., and Gladman D.D. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?. Arthritis Rheum 56 (2007) 840-849
16. Schmitt J.M., and Ford D.E. Role of depression in quality of life for patients with psoriasis. Dermatology 215 (2007) 17-27
17. Wilson F.C., Icen M., Crowson C.S., McEvoy M.T., Gabriel S.E., and Kremers H.M. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61 (2009) 233-239
18. Gisondi P., and Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 35 (2009) 313-324
19. McDonald C.J., and Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 99 (1978) 469-475
20. Mallbris L., Akre O., Granath F., Yin L., Lindelöf B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
21. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
22. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 129 (2009) 2411-2418
23. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
24. Gisondi P., Fantin F., Del Giglio M., Valbusa F., Marino F., Zamboni M., et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 218 (2009) 110-113
25. Ucak S., Ekmekci T.R., Basat O., Koslu A., and Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20 (2006) 517-522
26. Boehncke S., Thaci D., Beschmann H., Ludwig R.J., Ackermann H., Badenhoop K., et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 157 (2007) 1249-1251
27. Kaye J.A., Li L., and Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008) 895-902
28. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
29. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
30. Cohen A.D., Dreiher J., Shapiro Y., Vidavsky L., Vardy D.A., Davidovici B., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 22 (2008) 585-589
31. Wolf N., Quaranta M., Prescott N.J., Allen M., Smith R., Burden A.D., et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45 (2008) 114-116
32. Rocha-Pereira P., Santos-Silva A., Rebelo I., Figueiredo A., Quintanilha A., and Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303 (2001) 33-39
33. Wakkee M., Thio H.B., Prens E.P., Sijbrands E.J., and Neumann H.A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190 (2007) 1-9
34. Mallbris L., Granath F., Hamsten A., and Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006) 614-621
35. Campalani E., Allen M.H., Fairhurst D., Young H.S., Mendonca C.O., Burden A.D., et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154 (2006) 345-352
36. Chang C.F., Lin C.C., Chen J.Y., Yang A.H., Shiao M.S., Kao J.T., et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Am J Kidney Dis 42 (2003) 18-23
37. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
38. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
39. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
40. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
41. Johnston A., Arnadottir S., Gudjonsson J.E., Aphale A., Sigmarsdottir A.A., Gunnarsson S.I., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 159 (2008) 342-350
42. Naldi L., Addis A., Chimenti S., Giannetti A., Picardo M., Tomino C., et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology 217 (2008) 365-373
43. Clark L., and Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 58 (2008) 443-446
44. Gisondi P., Del Giglio M., Di Francesco V., Zamboni M., and Girolomoni G. Weight loss makes obese patients with moderate to severe chronic plaque psoriasis highly responsive to low dose cyclosporine: a randomized, controlled, investigator blinded, clinical trial. Am J Clin Nutr 88 (2008) 1242-1247
45. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
46. National Institute of Health. Third report of the national Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treament Panel III). Executive Summary. Bethesda, MD: National Institute of Health, National Hearth, Lung and Blood Institute; 2001. (NIH publ no 01-3670).
47. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
48. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
49. Levi M., Nieuwdorp M., van der Poll T., and Stroes E. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 34 (2008) 26-32
50. Nieuwdorp M., Stroes E.S., Meijers J.C., and Büller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 5 (2005) 155-159
51. de Alwis N.M., and Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 Suppl 1 (2008) S104-S112
52. Kotronen A., and Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008) 27-38
53. Targher G., Bertolini L., Padovani R., Rodella S., Tessari R., Zenari L., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007) 1212-1218
54. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009 [in press].
55. Marchesini G., Marzocchi R., Agostini F., and Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
56. Abiru S., Migita K., Maeda Y., Daikoku M., Ito M., Ohata K., et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26 (2006) 39-45
57. Loria P., Lonardo A., Bellentani S., Day C.P., Marchesini G., and Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 17 (2007) 684-698
58. Prodanovich S., Ma F., Taylor J.R., Pezon C., Fasihi T., and Kirsner R.S. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267
59. Rosenberg P., Urwitz H., Johannesson A., Ros A.M., Lindholm J., Kinnman N., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 46 (2007) 1111-1118
60. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61 (2009) 451-485
61. Vahlquist C., Olsson A.G., Lindholm A., and Vahlquist A. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol 75 (1995) 377-380
62. Antoniou C., Dessinioti C., Katsambas A., and Stratigos A.J. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 156 (2007) 1090-1091
63. Stinco G., Piccirillo F., and Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 157 (2007) 1273-1274
64. Dominique L. Liver toxicity of TNFalpha antagonists. Joint Bone Spine 75 (2008) 636-638
65. Gisondi P., Cotena C., Tessari G., and Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 22 (2008) 341-344
66. Saraceno R., Schipani C., Mazzotta A., Esposito M., Di Renzo L., De Lorenzo A., et al. Effect of anti-tumor necrosis factor- alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 57 (2008) 290-295
67. Franchimont D., Roland S., Gustot T., Quertinmont E., Toubouti Y., Gervy M.C., et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 90 (2005) 3510-3516
68. Dixon W.G., Watson K.D., Lunt M., and Hyrich K.L. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56 (2007) 2905-2912
69. Bosello S., Santoliquido A., Zoli A., Di Campli C., Flore R., Tondi P., et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27 (2008) 833-839
70. Nijsten T., and Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 129 (2009) 1601-1603